Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse

Regulatory Peptides

Volumn 154, Issue 1-3, 2009, Pages 85-90

  Wang, Hong Xia ^a   Zeng, Xiang Jun ^a   Liu, Yue ^b   Wang, Jue ^a   Lu, Ling Qiao ^a   Hao, Gang ^a   Zhang, Li Ke ^a   Tang, Chao Shu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

G protein coupled receptor; GPR14 or UT; Insulin resistance; Type 2 diabetes; Urotensin II

Indexed keywords

DEOXYGLUCOSE; GLUCOSE; INSULIN; MESSENGER RNA; RADIOLIGAND; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BINDING ASSAY; BINDING SITE; C57BL 6 MOUSE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DISSOCIATION CONSTANT; GLUCOSE TRANSPORT; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSULIN RESISTANCE; MALE; MOUSE; MOUSE STRAIN; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOLEMMA; SCATCHARD PLOT; SKELETAL MUSCLE; SOLEUS MUSCLE; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; RADIOLIGAND ASSAY; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; UROTENSINS;

MUS;

EID: 63049089471     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.01.004     Document Type: Article

References (42)

1. Bern H.A., Pearson D., Larson B.A., and Nishioka R.S. Neurohormones from fish tails: the caudal neurosecretory system. I: "urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res 41 (1985) 533-552
2. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., Conlon J.M., Bern H.A., and Vaudry H. Cloning of the cDNA encoding the urotensin II precurser in frog and human reveals intense expression of the urotensin II gene in motomeurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
3. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., Louden C.S., Foley J.J., Sauermelch C.F., Coatney R.W., Ao Z., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.S., Glover G.I., Wilson S., McNulty D.E., Ellis C.E., Elshourbagy N.A., Shabon U., Trill J.J., Hay D.W., Ohlstein E.H., Bergsma D.J., and Douglas S.A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
4. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 (2004) 1341-1344
5. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 (2002) 767-772
6. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jackel K., Scheffold T., Krakau I., Schramm M., Guelker H., and Stasch J.P. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
7. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davis J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
8. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., Kitada C., Miyajima N., Suzuki N., Mori M., and Fujino M. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
9. Mori Y., Otabe S., Dina C., Yasuda K., Populaire C., Lecoeur C., Vatin V., Durand E., Hara K., Okada T., Tobe K., Boutin P., Kadowaki T., and Froguel P. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 51 (2002) 1247-1255
10. Wenyi Z., Suzuki S., Hirai M., Hinokio Y., Tanizawa Y., Matsutani A., Satoh J., and Oka Y. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46 (2003) 972-976
11. Ong K.L., Wong L.Y., Man Y.B., Leung R.Y., Song Y.Q., Lam K.S., and Cheung B.M. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 27 (2006) 1659-1667
12. Watson A.M., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
13. Silvestre R.A., Rodriguez-Gallardo J., Egido E.M., and Marco J. Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res 33 (2001) 379-381
14. Clozel M., Hess P., Qiu C., Ding S.S., and Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316 (2006) 1115-1121
15. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104 (2003) 1-5
16. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., Kikuya M., Ohkubo T., Hashimoto J., and Imai Y. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
17. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., and Gilbert R.E. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44 (2004) 826-831
18. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., Ao Z., Maleeff B.E., Naselsky D., Disa J., and Aiyar N.V. Molecular and pharmacological characterization of genes encoding urotensin II peptides and their cognate G-protein coupled receptors from the mouse and monkey. Br J Pharmacol 136 (2002) 9-22
19. Notle L.A., Hansen P.A., Chen M.M., Schluter J.M., Gulve E.A., and Holloszy J.O. Short-term exposure to tumor necrosis factor- does not affect Insulin-stimulated glucose uptake in akeletal muscle. Diabetes 47 (1998) 721-726
20. Zachar V., Thomas R.A., and Goustin A.S. Absolute quantification of target DNA: a simple competitive PCR for efficient analysis of multiple samples. Nucleic Acids Res 21 (1993) 2017-2018
21. Wolff A.A., Hines D.K., and Karliner J.S. Refined membrane preparations mask ischemic fall in myocardial beta-receptor density. Am J Physiol 257 (1989) H1032-1036
22. +)-ATPase in rat heart during different phases of sepsis. Circ Shock 41 (1993) 19-25
23. Liu J., Sun H.B., Duan W.G., Mu D.Y., and Zhang L.Y. Maslinic Acid reduces blood glucose in KK-Ay mice. Biol Pharm Bull 30 (2007) 2075-2078
24. Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib Nephrol 151 (2006) 122-134
25. Wilkes J.J., Hevener A., and Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 52 (2003) 1904-1909
26. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujishiro M., Katagiri H., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Komura I., and Fujita T. Angiotensin II induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 (2002) 872-879
27. Giacchetti G., Sechi L.A., Rilli S., and Carey R.M. The rennin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16 (2005) 120-126
28. Marrero M.B., Fulton D., Stepp D., and Stern D.M. Angiotensin II induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 24 (2004) 2009-2013
29. Steensberg A., Keller C., Starkie R.L., Osada T., Febbraio M.A., and Pederson B.K. IL-6 and TNF-alpha expression in, and release from, contracting human skeletalmuscle. Am J Physiol Endocrinol Metab 283 (2002) E1272-1278
30. Pedersen M., Steensberg A., Keller C., Osada T., Zacho M., Saltin B., Febbraio M.A., and Pedersen B.K. Does the aging skeletal muscle maintain its endocrine function?. Exerc Immunol Rev 10 (2004) 42-55
31. Keller C., Steensberg A., Pilegaard H., Osada T., Saltin B., Pedersen B.K., and Neufer P.D. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15 (2001) 2748-2750
32. Jones A., and Woods D.R. Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol 35 (2003) 855-866
33. Shiuchi T., Iwai M., Li H.S., Wu L., Min L.J., Li J.M., Okumura M., Cui T.X., and Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43 (2004) 1003-1010
34. Shiuchi T., Cui T.X., Wu L., Nakaqami H., Takeda-Matsubara Y., Iwai M., and Horiuchi M. ACE inhibitor imp roves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40 (2002) 329-334
35. Henriksen E.J., Jacob S., Kinnick T.R., Youngblood E.B., Schmit M.B., and Dietze G.J. ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 277 (1999) R332-336
36. Sheffield-Moore M., and Urban R.J. An overview of the endocrinology of skeletal muscle. Trends Endocrinol Metab 15 (2004) 110-115
37. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24 (2003) 278-301
38. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., Steplewski K., Aiyar N., and Douglas S.A. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 238-250
39. Djordjevic T., BelAiba R.S., Bonello S., Pfeilschifter J., Hess J., and Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25 (2005) 519-525
40. Alessi M.C., and Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26 (2006) 2200-2207
41. Suguro T., Watanabe T., Ban Y., Kodate S., Misaki A., Hirano T., Miyazaki A., and Adachi M. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 (2007) 211-217
42. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123